Interim Management Statement

Vectura Group plc

Interim Management Statement

Chippenham, UK - 13 February 2013: Vectura Group plc (LSE: VEC) ("Vectura"), today publishes its Interim Management Statement for the period 01 October 2012 to 13 February 2013.

Pipeline update

NVA237/Seebri® Breezhaler® (COPD)

·; Following European and Japanese approvals on 28 September 2012, Seebri® Breezhaler® has been launched in, UK, Germany and Denmark, and Seebri® Inhalation Capsules in Japan

·; US filing expected in 2014

QVA149 (COPD) filed in Europe and Japan

·; QVA149 filed for marketing authorisation with the European Medicines Agency in October 2012, triggering a $5m (£3.1m) milestone

·; QVA149 filed with the Japanese Ministry of Health, Labour and Welfare in November 2012

·; US filing expected late 2014

VR315 (asthma/COPD), VR632 (asthma/COPD) and VR506 (asthma)

·; Solid development progress on all products

Financial update

On 20 November 2012, Vectura announced its interim results for the six months to 30 September 2012, reporting a profit after tax of £0.9m and cash of £72.1m.

Vectura's financial performance from 1 October 2012 to date has been in line with the Board's expectations.

Dr Chris Blackwell, Chief Executive of Vectura commented:

"The launch of Seebri® Breezhaler® in Europe, and Seebri® Inhalation Capsules in Japan, and regulatory filings of QVA149 by our partner Novartis during the period, are important milestones for Vectura. Looking ahead, we will soon enjoy royalty income from sales of Seebri® Breezhaler®, as well as additional near-term development milestones from this and other products in our pipeline that will further add to our robust financial position."

"The Company's strategy will continue to focus on value creation, evaluating suitable opportunities in established and emerging markets whilst carefully prioritising development and exercising tight control over expenses to manage our cash resources prudently. The Board remains confident in the Group's prospects."

Enquiries

About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.

Vectura has seven products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com.

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.